Please complete the ABSTRACT TEMPLATE online, for Biomed 2023 Company Presentations

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

All items marked with an * are mandatory to complete

The maximum number of **words** for this abstract is **400**

Please be sure to complete the following:

Company name--Aummune----- * Website-----https://aummune.com/---------- *

CEO name--------Irit Carmi Levy~~---------* Cell phone number----+972(0)523706847-----*~~

Select a CATEGORY: **Biotech/Pharma** *

(Delete categories you are not selecting)

Select up to two SESSIONS per abstract from the list below *

(Delete sessions you are not selecting)

3. Are Cancer Therapeutics Fulfilling the Promise?

You may delete the section instructions, leaving **only the bolded bullet title**

Answers below should not exceed 60 words per question:

- **Executive Summary / Investment Rational**

  Aummune is a clinical stage oncology company pioneering a unique patient-tailored platform to address key challenges in solid tumor therapy.
  A Phase I study with our lead asset AM003, a personalized immune-therapy for solid malignancies, is currently ongoing.

- **Core Technology**
  What is the technology, its uniqueness, and its value proposition?

  Aummune has developed a cutting-edge, proprietary platform, for the identification of a novel and unique drug per patient. This personalized drug is selected based on its ability to induce substantial tumor cell death of the patient's own cancerous cells while leaving healthy normal cells intact.

- **Product Profile/Pipeline**

  Aummune's therapeutic product is a Bispecific Personalized Aptamer. Its customized moiety is designed to selectively bind unique targets on the surface of tumor cells to induce tumor cell death, while the second moiety is designed to activate immune cells from the adaptive and innate compartments.
  Aummune's technology aims to disrupt both growing markets of personalized therapies and immunotherapeutics.

- **Business Strategy**

  Aummune's oncology therapies will be provided as an end-to-end service, from tissue sampling to computation, design, testing, and GMP production of the therapeutic DNA oligo molecules, to safe delivery of the therapeutic dose to the patient's hospital.

- **What's Next?**
  R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans

  Our lead program, AM003, has demonstrated efficacy and safety in several animal models. Following completion of the preclinical program and clearance from the Israeli regulatory authorities, a Phase 1 clinical study was initiated in Q3 2022. The First-in – Human study will enroll patients with locally advanced and metastatic solid tumors.